← back to search

Jamal Tarazi

Pfizer (United States) · US
Area of research
Pulmonary and Respiratory Medicine · Cancer Research
Research interest
Research interests include Renal cell carcinoma treatment, Cancer Genomics and Diagnostics, Cancer Immunotherapy and Biomarkers, and Cancer, Lipids, and Metabolism.
h-index
27
citations
5,335
works
100
NIH funding
primary concept
email

Recent publications

A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer
Clinical Cancer Research 2020cited by 65position: middledoi
Phase Ib Study of Crizotinib plus Pembrolizumab in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer with <i>ALK</i> Translocation
The Oncologist 2020cited by 34position: middledoi
Abstract GS4-07: Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor–positive breast cancer
Cancer Research 2018cited by 33position: middledoi
Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis
The Journal of Clinical Pharmacology 2013cited by 136position: middledoi
Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours
British Journal of Cancer 2012cited by 31position: middledoi
Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours
British Journal of Cancer 2012cited by 24position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Denka Markova · Crinetics Pharmaceuticals (United States)2 papers (2018–2020)Lainie P. Martin · University of Pennsylvania2 papers (2012–2012)Roger B. Cohen · University of Pennsylvania2 papers (2012–2012)Roy S. Herbst · Yale New Haven Hospital2 papers (2012–2012)Ahmad Awada · Institut Jules Bordet2 papers (2018–2020) · 2 papers (2012–2012)Thomas A. Samuel · Roswell Park Comprehensive Cancer Center2 papers (2012–2012)Claudio Zamagni · Azienda USL di Bologna2 papers (2018–2020)Tiffany A. Traina · Kettering University2 papers (2018–2020) · 2 papers (2012–2012)Mark Kozloff · Ingalls Memorial Hospital2 papers (2012–2012) · 2 papers (2012–2012)Ayca Gucalp · Memorial Sloan Kettering Cancer Center2 papers (2018–2020)Ian E. Krop · Cancer Institute (WIA)2 papers (2018–2020)Maureen Trudeau · Sunnybrook Health Science Centre2 papers (2018–2020)Laura Biganzoli · Azienda Usl Toscana Centro2 papers (2018–2020)Marco Colleoni · European Institute of Oncology2 papers (2018–2020)Patrick G. Morris · Hospital Universitario Virgen del Rocío2 papers (2018–2020)Eric P. Winer · Yale University2 papers (2018–2020)Anthony J. Olszanski · UCSF Helen Diller Family Comprehensive Cancer Center2 papers (2012–2012)